- 中文名稱
Relatlimab 生物類似藥, 人 LAG-3 單克隆抗體
- 英文名字
- Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody
- 供應(yīng)商
- Promab
- 產(chǎn)品貨號(hào)
- PMB-B00051
- 產(chǎn)品報(bào)價(jià)
- ￥詢價(jià)/1mg/5mg/20mg
- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購(gòu)買方式
- 90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞
- 背景資料
- What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3–blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer.nnRelatlimab and the anti–PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti–PD-1 monotherapy.
- 應(yīng)用類型
- Flow cytometry, animal model study
- 免疫原
- Human LAG-3
- 來源宿主
- CHO cells
- 反應(yīng)性
- Human
- 保存建議
- Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 其他
- Lymphocyte Activation Gene 3, LAG3, CD223, Cluster of Differentiation 223
- 注意
-
該頁(yè)面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說明書為準(zhǔn)。下單前，請(qǐng)瀏覽說明書確認(rèn)。
-
